Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Glenmark Pharmaceuticals Limited
  6. News
  7. Summary
    GLENMARK   INE935A01035

GLENMARK PHARMACEUTICALS LIMITED

(GLENMARK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Glenmark, Alembic, Ipca Invest in ABCD Technologies; Stakes of Dr. Reddy's, Others Reduced

05/03/2021 | 12:32am EDT


© MT Newswires 2021
All news about GLENMARK PHARMACEUTICALS LIMITED
06/15GLENMARK PHARMACEUTICALS  : launches Tiogiva®, becoming one of the first compani..
PU
06/08GLENMARK PHARMACEUTICALS  : releases interim data from PMS Study on Favipiravir
PU
06/04Glenmark Pharmaceuticals Gets US FDA Nod for Theophylline Extended-Release Ta..
MT
06/04GLENMARK PHARMACEUTICALS RECEIVES AN : Granted competitive generic therapy (CGT)..
PU
06/01GLENMARK PHARMACEUTICALS  : Launches Rufinamide Tablets
MT
06/01GLENMARK PHARMACEUTICALS  : launches Rufinamide Tablets USP, 200 mg and 400 mg
PU
05/31GLENMARK PHARMACEUTICALS'  : Consolidated Net Profit Climbs 6% in Fiscal Q4; Sha..
MT
05/28GLENMARK PHARMACEUTICALS  : consolidated revenues grow 2.8% to Rs. 1,09,439 Mn i..
PU
05/24GLENMARK PHARMACEUTICALS  : Gets US FDA's Approval for Icatibant Injection
MT
05/24GLENMARK PHARMACEUTICALS  : receives ANDA approval for Icatibant Injection, 30 m..
PU
More news
Financials
Sales 2021 111 B 1 506 M 1 506 M
Net income 2021 9 378 M 128 M 128 M
Net Debt 2021 31 873 M 434 M 434 M
P/E ratio 2021 19,8x
Yield 2021 0,38%
Capitalization 181 B 2 465 M 2 465 M
EV / Sales 2021 1,92x
EV / Sales 2022 1,76x
Nbr of Employees 14 000
Free-Float 47,4%
Chart GLENMARK PHARMACEUTICALS LIMITED
Duration : Period :
Glenmark Pharmaceuticals Limited Technical Analysis Chart | GLENMARK | INE935A01035 | MarketScreener
Technical analysis trends GLENMARK PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 624,30 INR
Last Close Price 640,90 INR
Spread / Highest target 17,8%
Spread / Average Target -2,59%
Spread / Lowest Target -20,6%
EPS Revisions
Managers and Directors
NameTitle
Glenn Mario Saldanha Chairman, Chief Executive Officer & MD
Jayaram Philkana President & Global Chief Human Resources Officer
V. S. Mani Chief Financial Officer & Executive Director
Sriram Venkatasubramanian President, Head-Global Operations & Supply Chain
Harish Kuber Secretary & Compliance Officer